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Abstract:  
The significant involvement of the gut microbiota in human health and disease suggests that 
manipulation of commensal microbial composition through combinations of antibiotics, 
probiotics and prebiotics could be a novel therapeutic approach. A systems perspective is needed 
to help understand the complex host– bacteria interactions and their association with 
pathophysiological phenotypes so that alterations in the composition of the gut microbiota in 
disease states can be reversed. In this article, we describe the therapeutic rationale and potential 
for targeting the gut microbiota, and discuss strategies and systems-oriented technologies for 
achieving this goal. 
 
Article: 
Most current searches for new drugs are focused on identifying a pharmacologically effective 
agent that specifically interacts with one molecular target in the eukaryotic host cell to regulate 
biochemical alterations in a diseased state and reinstate healthy- state biochemistry. During the 
past 30 years, such an approach has generated highly successful medicines. However, it does not 
completely exploit the complex regulatory network that has been engineered through 
evolutionary processes in humans, who could be viewed as ‘superorganisms’ with an 
indispensable internal ecosystem: the gut microbiota
1
. 
 
The human gastrointestinal (GI) tract is home to a complex consortia of trillions 
(approximately 1 x 10
13
 to 1 x 10
14
) of microbes, thousands of bacterial phylotypes, as well as 
hydrogen-consuming methanogenic archaea, colonizing the entire length of the gut with a 
collective genome (also termed as microbiome) that contains at least 100-times as many genes 
as our own genome
2
. Although largely unexplored and under-appreciated, our gut microbiota 
plays an intricate and sometimes pivotal role for our health and well-being. Emerging ‘omics’ 
technologies, such as metagenomics and metabonomics, are now being applied to the study of 
the gut microbial ecology at the molecular level, generating new insights and opportunities to 
reveal the medical functions of the gut microbiota to human health 
2–4
. 
 
Accumulating evidence indicates that the gut microbiota is instrumental in energy metabolism 
and immune function of the host, and has a crucial role in the development of numerous 
conditions including obesity
5,6
, diabetes
7
, non-alcoholic fatty liver disease
4
, inflammatory bowel 
diseases
8
, and even cancers
9
. Unlike the human genome, which is intact and rarely manipulated 
by xenobiotic intervention, the composition of commensal gut microbiota is readily changeable. 
The plasticity of the microbiome may allow a specific or systematic manipulation of certain gut 
microbiota associated with host diseases. Therefore, the exploration of the gut microbiota might 
not only revolutionize therapeutic strategies for many diseases, but also improve the pro-
ductivity of the pharmaceutical industry, which has recently made huge investments in the 
discovery of novel targets and drug candidates with limited success so far. With this in mind, 
this article provides perspectives for the therapeutic and prophylactic management of diseases 
and disorders that involve the gut microbiota, and suggests strategies for gut microbiota-oriented 
drug discovery. 
 
A microbial organ 
The human intestine is more densely populated with microorganisms than any other organ, and is 
a site where they exert strong influences on human biology. With this in mind, the entire system 
of the human gut microbiota can be pictured as a ‘microbial organ’ within the intestine, which 
contributes to diverse mammalian processes including protective functions against pathogens and 
immune-system modulation, the metabolic function of fermenting non- digestible dietary fibre, 
and the anaerobic metabolism of peptides and proteins that results in the recovery of metabolic 
energy for the host
10–12
. 
 
The intestinal mucosa is the main interface between the immune system and the external 
environment and therefore has an important role in the host–flora interaction. The commensal 
microbiota profoundly influences the development of humoral components of the gut mucosal 
immune system 
12,
 acting as a crucial factor in the prevention of exogenous pathogen intrusion. 
Metabolites, including digested dietary nutrients, are absorbed by the gut, and together with 
various non-nutrient compounds produced by the microbiota, are co-metabolized by host 
enzymes such as the cytochrome P450 and conjugating enzymes in the liver
13
. The resulting 
metabolites that are derived from both host and microbial processes are then returned to the gut 
by the bile and possibly other secretory routes for further metabolism and/or excretion. On one 
hand, the daily metabolism of food involving the different types of metabolic substrates and the 
secretion of peptic acid, bile and pancreatic fluids regulates the composition of the intestinal 
mucosa by hindering the colonization of the stomach and proximal small intestine by most 
bacteria, and changing the composition of enteric bacteria in the distal small intestine and the 
large intestine. On the other hand, commensal-derived metabolites and the composition of 
bacterial surface structures can have various effects on the host immune system
14
. Meanwhile, 
commensal bacteria can modulate gene expression in the host to create a suitable environment 
for themselves and prevent the growth of other competitive bacteria within the ecosystem
11
. 
 
 
 
Being such a microbial organ, our gut flora not only plays a significant role in disease onset and 
progression, but also influences drug bioavailability and toxicological incidence via microbial-
dependent drug metabolism. For example, the metabolism of ginsenosides, the principal 
bioactive components in Radix Ginseng. Ginsenoside Rb1, a saponin of protopanaxadiol, is 
metabolized by β-D-glucosidases in the gut microbiota into 20-O-β-D-glucopyranosyl-20(S)-
protopanaxadiol, which exhibits significant antitumour and anti-allergic activities
15
. A 
toxicological research programme, the Consortium on  Metabonomic Toxicology, has confirmed 
that the unusual metabolic profiles observed in a small proportion of the experimental rats treated 
with model toxic compounds are attributed to different gut microbiome contributions 16, 
suggesting that variations in drug metabolism under identical treatment are in direct association 
with the inter-subject diversity of the gut microbiota. 
 
A dynamic Pachinko model of metabolism, postulated by Nicholson and Wilson, suggests that 
the outcome of drug metabolism in mammalian transformation systems is not pre-arranged or 
determined absolutely, but is probabilistic and conditional on the sequence and sites of the 
previous metabolic events, and strongly influenced by the distribution of key metabolizing 
enzymes and transporter molecules
13
. It is therefore reasonable for an idiosyncratic toxicity to 
arise in selected individuals owing to unusual metabolic fates or interactions of drugs that are 
due to rare, but toxic, metabolic outcomes that become favoured by unusual combinations of 
genetic and environmental factors. With the same perspective, disease onset at a specific time 
point and with a unique phenotype among individuals can be considered a result of complex and 
probabilistic metabolic co-regulation by the host genome and the intrinsic microbiome in 
response to different dietary and environmental stress factors. 
 
The gut microbiota and diseases 
Recent publications have shown that the gut microbiota has a profound influence on the onset 
and progression of important human diseases that are currently lacking therapeutic solutions
5,9
. 
For example, differences in caloric extraction efficiency from food may be determined by the 
composition of the microbiota, which, in turn, may contribute to differential body weights
5
. Gut 
microbial species break down non-digestible polysaccharides and promote absorption of the 
resulting monosaccharides from the gut lumen, facilitating the induction of de novo hepatic 
lipogenesis. Additionally, fasting-induced adipocyte factor (FIAF; also known as ANGPTL4), a 
member of the angiopoietin-like family of proteins, is selectively suppressed in the intestinal epi-
thelium in the presence of enteric bacteria, leading to a microbiota-induced deposition of 
triglycerides in adipocytes 
17
 (FIG. 1). When mice are exposed to a high-fat diet, the gut 
microbial metabolism affects the conversion of choline into methylamines, reducing the 
bioavailability of choline to mimic the effect of a choline-deficient diet, and causing non-
alcoholic fatty liver disease
4
. These findings raise the possibility of manipulating the microbiotic 
environment to treat or prevent obesity and associated diseases. 
 
Certain environmental toxins such as dimethylarsine can be metabolized by specific strains of 
the gut resident Escherichia coli to produce potentially toxic micrometabolites, underlying the 
carcinogenicity of this type of compound in the gut
18
. Production of toxins, particularly 
neurotoxins or toxic metabolic products, by such microorganisms might also mediate 
neurological disruptions. We anticipate that a number of neurological disorders, such as 
attention–deficitlhyperactivity disorder (ADHD) and Tourette syndrome, which may be 
associated with this type of pathogenesis
19,20
, will eventually find treatment solutions in the gut 
microbiota. 
 
It is widely speculated, although controversial, that perturbations in the GI micro- biota 
composition as a result of the wide use of antibiotics in modernized countries may be linked to 
several conditions including obesity, insulin resistance, diabetes, irritable bowel syndrome and 
diarrhoea
21–23
. The mechanism behind this speculation is that in normal conditions, the stability 
of the microbial structure is maintained by the equilibrium of resident bacteria. However, this 
may be readily disrupted by antibiotics, leading to the overgrowth of antibiotic-resistant patho-
gens that are associated with numerous complex disorders, such as toxigenic Clostridium  
difficile-associated pseudomembranous colitis
24
. Additionally, antibiotics can have a long-term 
impact on the microbial ecology in our gut; a recent study shows that a short- term antibiotic 
exposure can have persistent consequences for individuals for up to 2 years post-treatment
25
. 
 
Taken together, it is apparent that changes in the Western lifestyle, together with the abuse of 
antibiotics in our body and our food chain, induce changes in the gut microbial ecology, such 
changes are likely to affect the genomic and metabolic predisposition of the host towards 
different energy storage 
 
 
capabilities, metabolic and immune regulatory networks, and pathologies. The gut microbiota 
could therefore be a previously under-appreciated source of drug targets for the treatment of 
metabolic disorders, various conditions in the GI tract and also neurological disorders. 
 
The gut microbiota as drug targets  
The knowledge and experience obtained from the management of chronic peptic ulcers induced 
by Helicobacter pylori suggests that certain chronic diseases are derived from the growth of 
particular microorganisms that are not inhibited by conventional biochemical modifications in 
eukaryotic host cells
26
, such microorganisms can be causative agents of disease and are therefore 
therapeutic targets, which necessitate modification with antibiotics and/or nutritional intervention 
as a realistic means for disease management. 
 
As we only possess limited knowledge of our gut microbiota and lack most of the molecular 
details of host–flora interactions, it may be too early to propose a clear microbiota-based drug 
discovery strategy or therapeutic modality. However, initial considerations of target candidates 
are expected to centre on those indigenous bacterial species with known genome sequences and 
biochemical functions, for example, Bacteroides  thetaiotaomicron is a Gram-negative anaerobe 
and a dominant member of the normal distal intestinal microbiota, which devotes a large 
proportion of its genome to metabolic processes that benefit the host and other commensal 
species
27
. It has an elaborate apparatus for acquiring and hydrolysing otherwise indigestible 
dietary polysaccharides and influences the transport and regulation of mammalian peroxisome 
proliferator-activated receptor-γ (PPARγ), an intranuclear receptor that is highly expressed in 
host adipose tissue and involved in the mechanism of human insulin resistance
28
. Certain 
pathogenic microbial species, which differ distinctly from healthy populations as a result of 
xenobiotic intervention and pathological development, could be identified as targets of interest 
for relevant treatment strategies. 
 
Compositional structures or patterns of the gut microbiota that are associated with  
certain diseases constitute a new type of drug target. such a concept evolves from recent  
work comparing the distal gut microbiota of genetically obese mice and their lean littermates, as 
well as those of obese and lean human volunteers, in which obesity was found to be associated 
with changes in the relative abundance of the two dominant bacterial divisions, the Bacteroidetes 
and the Firmicutes, and a dominant archaeon, Methanobrevibacter smithii
5,6,29
. Recent 
comparative genomic profiling analysis has revealed a wide distribution of the type III secretion 
system in commensal bacteria and pathogens
30
, which is not only a specific outcome of host cell 
infection, but also an indication of interactive communication between commensal bacteria and 
the host. Therefore, we speculate that different compositional structures of the gut microbiota in 
association with certain diseases may use different secretion patterns or modes to communicate 
with host cells and participate in the host metabolic network. These different secretion patterns 
may produce a characteristic secretome or small-molecule metabonome that could be measured 
by biochemical analysis of urinary and faecal samples. further studies are expected to determine 
whether commensal bacteria with certain compositional structures will mediate the host immune 
surveillance in the gut by means of specific secretion patterns. Moreover, the ‘omics’ sciences 
such as metabonomics and proteomics can be utilized to monitor the subtle variation resulting 
from different compositional structures of commensal bacteria under certain pathological 
conditions. 
 
Gut microbiota-targeted therapies  
We envisage that two strategies may be taken for the development of future gut microbiota-
targeted therapies. The first is the direct elimination or modification of a well-defined, 
specific gut microorganism, or certain species of bacteria, as disease target(s), in a similar 
way to the treatment of chronic peptic ulcer induced by H. pylori using antibiotics
31
. An 
alternative method for such a strategy is vaccination using an antigenic epitope of a 
bacterium or toxin of interest to elicit an immune response capable of interacting with the 
gut flora upon microbe proliferation in the gut. However, limitations of these methods may 
include the lack of specificity of the broad-spectrum antibiotics and the vaccination systems 
available, which will result in unexpected destruction of the beneficial microbial community 
and a long-term disturbance of gut ecology. Additionally, the frequent exposure of the gut 
microbiota to antibiotics or vaccines 
 
may induce rapid genetic modification of the gut microbiota, which would accelerate the 
development of resistance to such therapeutic means. A thorough molecular understanding of 
host–flora interactions and pathologies is a prerequisite for these therapeutic approaches to be 
effectively conducted with minimal long-term adverse consequences. 
 
The second strategy is to take a holistic approach, similar to that practiced in traditional Chinese 
medicine, in which various diseases and conditions are categorized into different syndromes 
based on a patient’s clinical manifestations such as pulse, tongue images and information of 
urine and excrements, before a treatment is applied. In this strategy, different structural patterns 
of the gut microbiota that are associated with different clinical manifestations are identified and 
categorized using profiling methods such as metabonomics and metagenomics. The metabolic or 
genomic profiling of the gut microbiota from plasma, urinary or faecal samples could allow a 
stratification of certain gut microbiota structures in association with disease phenotypes. 
Combinations of antibiotics, probiotics, prebiotics and perhaps laxatives could be used to 
manipulate the gut microbiota to achieve a therapeutically effective regimen and, eventually, 
restore the homeostasis of gut ecology in the host (Fig. 2). 
 
Probiotics are live microorganisms that are frequently used as dietary regulators to influence the 
gut microbiota composition, and confer beneficial effects on the host when adequately 
administered. Bacterial constituents or secreted metabolites, such as antimicrobial peptides 
(bacteriocins), may also contribute to the bioactivities of probiotics
32
. Efficient probiotic strains 
have been found in different bacterial genera including Bifidobacteria, Lactobacilli, Streptococci 
and non-pathogenic E. coli, and even nematode parasites. Many probiotic effects, including 
resistance to infection, improvement of allergic diseases and anti-inflammatory properties, are 
achieved by modifying the host immune response. For example, the enhancement of phagocytic 
activity of peripheral blood leukocytes and natural killer cells, and the stimulation of both 
nonspecific secretory immunoglobulin A (IgA) and a specific antibody response
33
. Recent 
research in enteric bacteria indicates that the use of probiotics is rapidly advancing from the field 
of nutrition or dietary supplementation towards therapeutic applications for various conditions. 
Oral administration of Lactobacillus casei in diabetic KK-Ay mice has been shown to 
significantly decrease plasma glucose levels and inhibit the production of B-cell specific CD4
+
 T 
cells and cytokines — interferon-γ (IFNγ) and interleukin 2 (IL2) — which are leading factors 
involved in the induction of autoimmune diabetes
34
. In addition, studies have found that L. casei 
could inhibit the alloxan-induced disappearance of pancreatic B cells in mice
35
, which can also 
inhibit the autoimmune destruction of pancreatic B cells in non-obese diabetic mice
36
. similarly, 
Lactobacillus GG feeding delays the development of glucose intolerance and hyperglycaemia in 
streptozotocin-induced diabetic rats
37
, and a significant anti-diabetic effect of a probiotic 
containing Lactobacillus  acidophilus and L. casei has been observed in high-fructose fed rats
38
. 
Additionally, some probiotics may also induce defensins in epithelial cells, which are natural 
antimicrobial peptides secreted in the intestine 
39. 
 
Prebiotics are a group of non-digestible food ingredients including inulin, oligosaccharides, 
lactulose and resistant starch that are fermented by colonic commensal micro- biota to potentially 
improve host health by selectively stimulating the growth of certain gut bacteria
40
. Although 
their targets are traditionally believed to be Bifidobacterium spp. and Lactobacillus spp., 
prebiotic ingredients may work through the selective stimulation of various indigenous beneficial 
strains to exert antimicrobial effects, or to modulate immune responses of the host and compete 
with pathogens for receptors. 
 
both prebiotics and probiotics have been shown to decrease the incidence and severity of 
infantile diarrhoea, and prevent antibiotic-induced diarrhoea or food allergies
41
. Additionally, 
dietary intervention using a combination of probiotics and prebiotics, known as synbiotics, is a 
feasible treatment strategy and has proven to be efficacious in volunteer trials in patients with 
active ulcerative colitis
42
. Examples of gut microbiota-related diseases and therapeutic strategies 
are provided in TABLE 1. 
 
The fact that a significant portion of bioactive metabolites produced in animals and medicinal 
plants are found to be synthesized or co-synthesized by their commensal microbiota suggests that 
the gut microbiota itself may be a largely untapped source of novel drugs or drug leads
43
. several 
anticancer metabolites from marine sponges, including discodermolide, halichondrin b and bryo-
statin 1, have progressed to preclinical or clinical-trial phases, and are thought to be products 
derived from their microbiotic consortia
44
. Therefore, the commensal microbiota can potentially 
be engineered as a bioreactor using new cloning and biosynthetic expression strategies for the 
controlled secretion of biologically active molecules and vaccines. A new class of 
pharmaceutical compounds derived from the uncultured commensal microorganisms in 
appropriate in vitro or animal models may be produced to develop a long-term host 
immunotherapy for diseases such as inflammatory bowel disease. Currently, the application of 
culture-independent metagenomic technology sheds light on the opportunities of drug discovery 
from the gut microbiota. The integration of high-throughput DNA sequencing and bioinformatics 
tools enables the identification of genes encoding bioactive compounds from the commensal 
microbiota. The genes of interest, isolated directly from commensal bacteria or screened from a 
clone library using genome-sequence tags, could be cloned into optimal vectors and transformed 
into surrogate hosts to encode biosynthesis of novel therapeutic products. 
 
Platform technologies for the microbiota 
 The development and utilization of appropriate technologies that allow comprehensive and 
robust analyses for various microorganisms, most of which are non-culturable, are crucial for 
understanding the impact of the gut microbiota on the host. The established metabolic profiling 
approach has a powerful capacity for detecting various metabolites originating from 
microorganisms that are commonly found in mammals. several analytical techniques, including 
high resolution nuclear magnetic resonance (NMR) spectroscopy
45
 and various gaslliquid chro-
matography–mass spectrometry (GC–Ms, LC–Ms) techniques
46,47
 are currently used to generate 
spectral profiles from which information pertaining to pathophysiology can be extracted. for 
example, the aromatic region of a typical 
1
H NMR spectrum of urine provides a clear window 
for visualization of metabolic signature of microbial products, dietary metabolites or parasite-
related metabolites
48,49
. On the basis of a metabolic profiling approach, the concept of 
pharmacometabonomics, proposed by Clayton et al.
50
 in 2006, highlights the application of such 
technology to personalized treatment, in which drug-induced responses in individuals can be 
predicted from a pre-dose metabolic signature. This concept was demonstrated in two classic rat 
models of dietary-induced obesity and streptozotocin-induced diabetes, in which only certain 
animals acquired obese or hyperglycaemic phenotypes
51
. 
 
The different outcomes of streptozotocin or dietary intervention were closely associated with 
variations in pre-dose urinary metabolites that had been reported to originate from gut microbiota 
metabolism
52
, therefore linking the phenotypic variations to the different pre-dose compositional 
structures of the gut microbiota (Fig. 3.) 
 
Metagenomics, also known as community genomics, provide an insight into the genetic potential 
of complex microbial communities, including uncultured species, using culture-independent 
approaches
53
. It has been used in digestive ecosystems to discover novel hydrolase genes in 
uncultured rumen bacteria and P-glucanase genes affiliated with uncultured microbiota that 
colonized the large bowel of mice. Currently, screening approaches for intestinal metagenomic 
libraries have not been fully established. With the progress in molecular technologies, the most 
comprehensive 16s ribosomal DNA (rDNA) sequence-based metagenomic approach has been 
successfully applied in the analysis of the distal gut and faecal micro-biota. This analysis 
revealed significant differences in community membership between healthy adults
54
, which may 
contribute to variations in physiology between individuals or in factors that predispose to 
disease. 
 
Transplantation of human gut microbiota into surrogate hosts, such as mice or rats, may allow 
the generation of animal models that mimic human flora and facilitate the in-depth research on 
human gut microbiota-associated metabolism, pharmacology and immunity
55
. However, the 
intrinsic differences between rodents and humans in anatomy and physiology make it difficult to 
directly extrapolate the results. A new human flora-associated piglet model was recently 
established by the transplantation of human GI microbiota to germ-free piglets with minimal 
individual variation and ageing patterns that are similar to those observed in humans
56
. such a 
human flora-mimicking piglet model provides a new platform for pharmacological and 
biochemical research for gut pathology, nutraceutical and pharmaceutical compound screening, 
and drug metabolism. 
 
Concluding thoughts: a systems approach 
 Gut microbiota-oriented pharmaceutical research requires a progressive, experimental pipeline 
approach that is dedicated to such a process. Understanding the global relationships between the 
gut microbiota and humans — for example, a common aetiology for both GI and 
neurologicallmetabolic disorders — is the first step towards establishing novel diagnostic, 
therapeutic and preventive modalities for such diseases. strategies that are guided by systems 
thinking need to be adopted in order to understand the essential elements that are involved in the 
onset and development of many complex human diseases that are associated with variations in 
the gut microbiota. focusing on the totality of the microbiota and, therefore, capturing the global 
change of the gut microbiota with pathological and pharmacological significance is the key to 
generating comprehensive molecular descriptions of the disease and multifaceted, system-wide 
drug responses, so that the breadth of biochemical changes contributing to a disease or drug 
response can be taken into account. research programmes focusing on certain clinical 
manifestations or phenotypic variations of a disease associated with altered gut microbiota need 
to be conducted to classify the disease so that different therapeutic strategies can be implemented 
for different subtypes or states of gut ecology associated with different structures of the 
microbiota. bioanalytical profiling technologies, such as metabonomics and metagenomics, of 
patient urinary and faecal samples can be utilized to provide holistic and dynamic biochemical 
information to assist the medical staff on disease diagnosis, stratification and personalized gut 
microbiota-targeted treatment. Meanwhile, elucidating the molecular details of host–flora 
interactions during a pathological process should be pursued to obtain a mechanistic 
understanding to aid drug development. such a top-down strategy is crucial to achieving a 
complete coverage of the biochemical mechanisms contributing to the disease to generate 
feasible treatment measures. 
 
So far, engineering ecologies (the living environments outside and inside of our bodies) has not 
been that successful because of an incomplete understanding of the systems involved. Currently, 
we still have limited mechanistic knowledge regarding how indigenous microorganisms have 
shaped our genome and biology in postnatal development. Emerging technologies, such as 
metabonomics and metagenomics, have provided information indicating that symbiotic microbes 
affect metabolic phenotypes and enzyme induction states, which ultimately affect the outcome of 
interventions
4
. Growing evidence continues to reveal important functions of the gut microbiota 
in human health and provides new therapeutic targets for the drug industry that, so far, has been 
focusing exclusively on the human genome. We assert that the value of gut microbiota-targeted 
drug discovery and therapies can only be fully realized by a major shift from studying the parts 
of living systems in isolation, or the reductionist approach, to studying the intricate 
interrelationship within our superorganism by integrating results from different scientific 
disciplines — the systems approach. The host–flora interaction must be composed of complex, 
networked communications involving convergent, divergent and redundant signalling pathways. 
Considering the infrastructures for platform technologies to be established and the need to attract 
cross-disciplinary research personnel, a long-term agenda and research strategy, perhaps 15–20 
years in duration, is required for the full development of this field. With the progress of 
metagenomics in conjunction with other ‘omics’ technologies, the composition and specific 
biological functions of the human gut microbiota will be gradually uncovered, opening up an 
entirely new approach to drug discovery and therapy. 
 
 
 
 
